Alkermes Inc 2018 Q4 Big Money Sentiment Better Than Expected, now at 0.87

Positions for Alkermes Inc (NASDAQ:ALKS)

In 2018 Q4 Alkermes Inc (NASDAQ:ALKS) big money sentiment decreased to 0.87, SEC filings reveal. So its down -0.30, from 2018Q3’s 1.17. 90 investment managers increased and started new equity positions, while 104 decreased and sold holdings in Alkermes Inc so the sentiment dived. These funds own 149.02 million shares, that’s down from 152.54 million shares in 2018Q3. Funds holding Alkermes Inc in top 10 changed to 1 from 1 for the same number . 37 Investors Sold All; 67 Reduced Holdings; 60 increased holdings while 30 investment managers bought holdings.

Largest Alkermes Inc Shareholders

Meditor Group Ltd owns 892,400 shares in Alkermes Inc as of 2018 Q4. As of 2018 Q4, 56,161 shares of Alkermes Inc are owned by Roanoke Asset Management Corp Ny. In addition, First Light Asset Management Llc reported 170,533 shares in Alkermes Inc equivalent to 0.8% of its US equity exposure. Bogle Investment Management L P De revealed 307,992 shares position in Alkermes Inc. The Sweden-based fund Rhenman & Partners Asset Management Ab holds 174,399 shares or 0.59% of their US equity exposure.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide.The company has $5.18 billion market cap. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes.Currently it has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

The stock decreased 1.07% or $0.36 during the last trading session, hitting $33.17.Currently Alkermes plc is downtrending after 40.70% change in last March 15, 2018. ALKS has also 643,396 shares volume. ALKS underperformed the S&P 500 by 45.07%.

Alkermes plc (NASDAQ:ALKS) is awaited to announce earnings on April, 25., according to Faxor. This year’s EPS analyst estimate is awaited to be $-0.38. That is 90.00 % down compareed to $-0.2 EPS for last year. -323.53 % negative EPS growth is what analysts predict. $0.17 EPS was published for previous quarter.

Fifth Third Bancorporation holds 87 shs or 0% of its capital. 504,800 are held by Swiss Natl Bank. Reilly Financial Advsrs Ltd stated it has 0% in Alkermes plc (NASDAQ:ALKS). Creative Planning holds 18,927 shs. Hall Laurie J Trustee holds 0.04% or 2,600 shs in its capital. First Trust Advsr Lp stated it has 2.25M shs. Dekabank Deutsche Girozentrale invested 0.02% of its capital in Alkermes plc (NASDAQ:ALKS). Quantitative Investment Mngmt Ltd Liability owns 0.02% invested in Alkermes plc (NASDAQ:ALKS) for 15,500 shs. Canada Pension Plan Board reported 776,050 shs stake. Rhenman & Prtnrs Asset Management holds 174,399 shs or 0.59% of its capital. Cibc Asset accumulated 7,472 shs. Daiwa Securities Grp, a Japan-based fund reported 35,015 shs. Toronto Dominion National Bank & Trust reported 20,915 shs. Ls Investment Advisors Limited Liability Company reported 1,908 shs. Td Capital Management Limited Liability Company owns 20 shs for 0% of their capital.

Alkermes plc (NASDAQ:ALKS) Ratings Coverage

In total 8 analysts cover Alkermes (NASDAQ:ALKS). “Buy” rating has 0, “Sell” are 2, while 6 are “Hold”. (NASDAQ:ALKS) has 0 bullish analysts. With $41 highest and $26 lowest target, Alkermes has $33.83 average target or 1.99% above the current ($33.17) price. 10 are the (NASDAQ:ALKS)’s ratings reports on 15 Mar 2019 according to StockzIntelligence Inc. On Wednesday, December 19 Goldman Sachs downgraded the shares of ALKS in report to “Sell” rating. In Thursday, December 13 report Credit Suisse downgraded the stock to “Underperform” rating. On Tuesday, November 6 the stock has “Neutral” rating by Cantor Fitzgerald. On Monday, March 11 the firm has “Sell” rating given by Morgan Stanley. On Friday, February 15 the firm earned “Hold” rating by Credit Suisse. In Thursday, February 14 report Cantor Fitzgerald maintained the stock with “Hold” rating.

For more Alkermes plc (NASDAQ:ALKS) news released recently go to:,,, or The titles are as follows: “Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) and YRC Worldwide Inc. (YRCW): Bronstein, Gewirtz & Grossman, LLC Class Action Update – GlobeNewswire” released on February 19, 2019, “Health Care Sector Update for 02/19/2019: CNDT,ICPT,CLVS,ALKS – Nasdaq” on February 19, 2019, “REVIEWAPALOOZA!: 5-Stock Samplers – Motley Fool” with a publish date: March 06, 2019, “Alkermes’ (ALKS) and Biogen’s NDA for BIIB098 Accepted by FDA – Nasdaq” and the last “Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference – PRNewswire” with publication date: March 05, 2019.

Alkermes plc (NASDAQ:ALKS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.